RVMD RVMD
Company Profile ↓Company Overview
RVMD (RVMD) is a publicly traded company listed on with a market capitalization of $38.87B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +438.63% |
| 6 Months: | +105.59% |
| 3 Months: | +34.03% |
| 1 Month: | +3.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.22 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.17M | 12.28M | 12.51M | 12.09M | 11.55M | 10.03M | 12.66M | 8.75M | 10.13M | 8.70M | 1.10M | 7.58M | 9.12M | 3.36M | 7.01M | 3.82M | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 240.76M | 264.71M | 315.27M | 361.63M | 445.22M |
| Operating Income | -10.44M | -10.56M | -13.56M | - | -21.08M | -27.98M | -27.55M | - | -37.40M | -44.53M | -53.16M | -57.95M | -62.09M | -76.53M | -75.16M | -108.80M | -123.25M | -140.86M | -156.64M | -175.71M | - | -240.76M | -264.71M | -315.27M | -361.63M | -445.22M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -237.04M | -260.91M | -289.44M | -348.25M | -437.08M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.43M | 11.94M | 12.20M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -213.42M | -247.79M | -305.21M | -364.89M | -453.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -753.00K | - | - | - | - | - |
| Net Income | -10.13M | -10.12M | -12.82M | -14.60M | -19.52M | -27.21M | -27.22M | -34.20M | -37.18M | -44.30M | -52.94M | -57.65M | -61.22M | -73.33M | -68.10M | -98.30M | -108.43M | -116.00M | -133.23M | -156.29M | - | -213.42M | -247.79M | -305.21M | -364.89M | -453.82M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.60 | -0.72 | -0.78 | -0.82 | -0.87 | -0.72 | -0.92 | -0.99 | -0.70 | -0.81 | -0.94 | - | -1.13 | -1.31 | -1.61 | -1.86 | -2.29 |
| R&D Expense | 21.19M | 20.12M | 22.96M | - | 27.46M | 32.92M | 34.87M | - | 40.86M | 45.94M | 46.47M | 56.49M | 61.00M | 69.45M | 68.95M | 97.98M | 107.73M | 118.02M | 134.93M | 151.75M | - | 205.75M | 224.13M | 262.51M | - | 343.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.16M | 50.04M | 42.98M | 29.39M | 35.38M | 11.58M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 293.66M | 498.76M | 689.52M | 1.18B |
| Operating Income | -40.33M | -54.12M | -110.70M | -188.01M | -258.28M | -487.19M | -689.52M | -1.18B |
| EBITDA | - | - | - | - | -248.62M | -430.58M | -589.02M | -1.09B |
| Interest Expense | - | - | - | - | 0 | 0 | 0 | 24.23M |
| Pretax Income | - | - | - | - | -249.12M | -439.89M | -600.85M | -1.13B |
| Tax Provision | - | - | - | - | -420.00K | -3.52M | -753.00K | 0 |
| Net Income | -41.79M | -47.66M | -108.16M | -187.09M | -248.71M | -436.37M | -600.09M | -1.13B |
| Diluted EPS | - | - | -2.01 | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 |
| R&D Expense | 51.08M | 91.75M | 132.25M | 186.95M | 253.07M | 423.14M | 592.23M | 987.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 220.53M | 567.40M | - | 811.93M | 2.06B | 2.56B | 2.35B |
| Current Assets | - | - | - | - | - | 660.18M | 1.88B | 2.33B | 2.08B |
| Cash & Equivalents | - | 69.59M | 16.66M | 104.27M | - | 161.41M | 696.15M | 543.06M | 383.75M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 5.93M | 4.67M | 1.25M | 0 | - |
| Total Liabilities | - | - | 67.99M | 92.72M | - | 126.74M | 235.51M | 293.10M | 723.21M |
| Current Liabilities | - | - | 43.05M | 47.18M | - | 61.98M | 143.85M | 163.91M | 290.42M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 64.20M | 87.94M | 135.84M | 158.70M |
| Total Equity | -67.72M | -108.42M | -152.57M | 474.68M | - | 685.19M | 1.83B | 2.27B | 1.63B |
| Shares Outstanding | - | - | - | - | - | 90.41M | 164.67M | 185.90M | 197.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.21M | -49.62M | -100.06M | - | -224.40M | -350.57M | -557.44M | -897.74M |
| Investing Cash Flow | -1.34M | -101.97M | -234.23M | - | -24.12M | -342.60M | -554.39M | 118.06M |
| Financing Cash Flow | 60.85M | 98.66M | 422.78M | - | 301.43M | 1.23B | 959.41M | 621.52M |
| Capital Expenditure | -1.50M | -2.59M | -2.93M | - | -10.82M | -7.73M | -10.31M | -15.99M |
| Free Cash Flow | -286.00K | -52.20M | -103.00M | - | -235.22M | -358.30M | -567.74M | -913.73M |
| Net Change in Cash | - | - | - | - | 52.91M | 536.03M | -152.42M | -158.16M |
| Dividends Paid | - | - | 0 | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -200.0% | -108.2% | -257.5% | -639.7% | -730.0% | -4,207.1% | - | - |
| Net Margin % | -207.2% | -95.2% | -251.6% | -636.6% | -703.0% | -3,768.3% | - | - |
| ROE % | 38.5% | 31.2% | -22.8% | - | -36.3% | -23.9% | -26.5% | -69.3% |
| ROCE % | - | -30.5% | -21.3% | - | -34.4% | -25.4% | -28.8% | -57.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RVMD
Revolution Medicines (RVMD) Stock Looks Fully Priced With Strong Returns But Weak Value Checks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOd2xOWUEwOC1ucVRuUTRDMXowZVVYX0Q1aExITk5LcFdWWDVsUWgxZ0RyQkRGelpoWXJFOTBwM0VhWXVIMXR2Y0U0VFVyYkhUOEpybUoyQ3ltRXdYX1NWSU5mRG02Q1ctV0xnM2R3bGV5bzFJOEFlZUtUSU5pV1Nwc3RxNXNBbXkzbHMyZV…
Oral Investigational Medicine for Pancreatic Cancer Is Accepted for FDA Review - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPTGh3cGZQMmhKVEZoa0RrQXhGd2FJdVh6T0FuLXFmNGh6MmtQVHhwcVRRbElDd0tXZUw5NlZhYmxvRXB1d2dKYXdJY2FpRDlIaVhfaVlwMEJuaUg0NHlQTGF5RmJ3WFJJZXBCNi0zRnhMSmU1WER0WnRvUDZZX1NwUEpiYkxJb3lBZ3Bva0…
Anti-Cancer Upstart’s Stock Surges 125% This Year as Billionaire Druckenmiller Builds Large Position - NAI500
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQQmZxbGplNEQtalR4Q1pnWTA3Tjg0dFVfSzNFRXJoVGN1U19sSWdJMDI2UUN0LTQ2a0hISUhqbFhDRkx0UUkzZWxNMkpVU1R2aTE3N21jTlo5Tjhxd2ZzMW12eUh2RzFscm1oQ0U5ZVg0WnBpOEJIYk12UFRzaXp2UXpMV090ZlFodXVqZm…
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPMkg1Z2JZaGdMdHJfXzVSTlhOTzJfMXhuYlE1MkxUWWxNaUw3ZWU3U1RPRlNjcmQ4WU1VazNXMDhReVlaaTFuQ2RDSGdRcnRRSk5qLU5vUVhCU3RRNUtKOHFUOTBrWV9OSFNCTW5lNzh0TEtNVlphY1NKSUNSdWVDX3ZEOFpZQ0YyOE84dG…
Revolution Medicines falls on second quarter earnings miss By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPaHk4NGhLcy1RT2p5eEFHSGxjWFB5OTh2QlY3Uk5KTXQ2OE5JX1VyMlp1alVaNHZIYlNOaTAtWGxPQlo3c3hzbGZFVkFGYmVpTjBydUQ5dzRUdnRhZVN1YUxTNVR2MmNJRHFLQzlRR2d2Wk40cUFoRjBDXzZnc1ktV1VacXI5VHFyRWVZQk…
Is Revolution Medicines (RVMD) Fully Valued Following Its FDA Filing Win? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPeHpDMlcyaUhxcVhVLV9vbWZtdWNreTNlTHpWek9oeVd4cGozb25sb0ItMUt1WHUxS1NGTGxBdHJvMXQtQW9XSFNBbDB3QThqYUcwSXFxTzFkazFCczUxMV9XUlU0Z1RlelREM3pnUDg5cWVSVHZiZDFNamxjb2I0eVh4Yk00QndxMWV2MV…
RVMD — Frequently Asked Questions
What is the current share price of RVMD?
As of 2026-08-05 17:25 PDT, RVMD trades at $197.30 on NASDAQ/NYSE. Its 52-week range is $34.70 to $197.30.
What is the market capitalisation of RVMD?
RVMD has a market capitalisation of $38.87B on NASDAQ/NYSE.
What is the P/E ratio of RVMD?
RVMD trades at a trailing price-to-earnings (P/E) ratio of -33.16. Its price-to-book (P/B) ratio is 23.83.
What is the return on equity (ROE) of RVMD?
RVMD has a return on equity (ROE) of -69.35%. Its return on capital employed (ROCE) is -57.28%.
Is RVMD a good stock to buy?
This page provides a data-driven analysis of RVMD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.